Novo Nordisk A/s

Jakob Ewald Rasmussen

Per Sauerberg

Thomas Kruse

Thomas Hoeg-Jensen

Henning Thoegersen

Carsten Behrens

Miroslav Havranek

Mikael Kofod-Hansen

Henning Thøgersen

Martin Werner Borchsenius Muenzel

Ivan Snajdr

Ladislav Droz

Zuzana Drobnakova

Vladislav Kotek

Milan Stengl

Hana Drusanova

Vojtech Balsanek

Henning THØGERSEN

Thomas HØEG-Jensen

Zuzana DROBNÁKOVÁ

Miroslav HAVRÁNEK

Hana VÁNOVÁ

Martin Werner Borchsenius MÜNZEL

Vojtech BALSÁNEK

Mikael Kofoed Hansen

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Glucose-sensitive albumin-binding derivatives

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X&#x2014;R2, and wherein 'X' is a mono- to multiatomic linker and where Rand R, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1&#x2032;-X&#x2032;&#x2014;R2&#x2032;, in which either the moeities R1&#x2032; or R2&#x2032; or X&#x2032; carry a drug that is covalently attached to the diboron compound.

Growing community of inventors

Copenhagen, Denmark

Jakob Ewald Rasmussen